MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.50 Consensus Price Target from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. […]
